Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Since the introduction of immune modulators in the treatment of rheumatoid arthritis (RA), there has been hope that orally effective biologic agents would be developed. Tofacitinib, a Janus kinase inhibitor, has become the first oral biologic to receive approval for use in active RA patients. This p...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736471/ |